The Global Synthetic Biology Market was valued at USD 25.6 billion in 2025 and is estimated to grow at a CAGR of 17.5% to reach USD 128.1 billion by 2035.
The market is witnessing strong momentum as synthetic biology integrates engineering principles with biological systems to design and construct novel biological components, devices, and systems. The field has evolved significantly from traditional genetic engineering approaches toward advanced platforms that enable precise and programmable control of cellular behavior. This transformation has been accelerated by rapid advancements in DNA sequencing and synthesis technologies, computational biology tools, and deeper insights into biological system design. The ecosystem spans enabling inputs such as oligonucleotides, enzymes, and chassis organisms, core outputs including synthetic genes, engineered cells, and DNA libraries, and downstream applications across pharmaceuticals, industrial chemicals, biofuels, and biomaterials. Increasing adoption of genome editing technologies, particularly CRISPR-based platforms, is further expanding applications across healthcare, agriculture, and industrial biotechnology, supporting broad-based market growth.
The enabled products segment accounted for 67.5% share in 2025 and is expected to grow at a CAGR of 17.4% through 2035. This segment leads the market as it includes commercially deployable outputs such as engineered biomolecules, industrial enzymes, bio-based chemicals, sustainable fuels, advanced materials, agricultural biologicals, and therapeutic solutions. Strong revenue generation is supported by direct industrial commercialization and widespread integration across multiple end-use sectors.
The pharmaceuticals and diagnostics segment held a 78.8% share in 2025 and is projected to grow at a CAGR of 17.2% through 2035. It remains the most established application area, driven by engineered biological systems in drug discovery, vaccine development, gene and cell therapy research, and molecular diagnostics. Synthetic biology enables highly precise, reproducible, and customizable medical solutions, accelerating the development of advanced therapeutic and diagnostic platforms.
North America Synthetic Biology Market accounted for 39.6% share in 2025. The region maintains a strong position due to advanced research infrastructure, early adoption of biotechnology innovations, and a highly developed ecosystem that includes academic institutions, startups, and large biotechnology and pharmaceutical companies, supporting continuous technological advancement and commercialization.
Major players operating in the Global Synthetic Biology Industry include Twist Bioscience, GenScript, Integrated DNA Technologies, Thermo Fisher Scientific, Novozymes, BASF, Royal DSM, Amyris, Gevo Inc, and Bristol-Myers Squibb. Companies in the Synthetic Biology Market are prioritizing heavy investment in advanced genome engineering platforms, including CRISPR-based technologies and automated DNA synthesis systems, to improve precision and scalability. They are strengthening R&D capabilities through collaborations with academic institutions and biotechnology startups to accelerate innovation pipelines. Expansion into high-growth application areas such as therapeutics, sustainable chemicals, and industrial bioproducts is also a key focus to diversify revenue streams. Firms are increasingly adopting integrated platform strategies that combine software, automation, and biological design tools to reduce development timelines. Strategic partnerships and licensing agreements are being used to access proprietary technologies and expand global reach. In addition, companies are investing in scalable biomanufacturing infrastructure to support commercialization, while also focusing on regulatory compliance and quality assurance to ensure safe and efficient market adoption.
This product will be delivered within 2-4 business days.
The market is witnessing strong momentum as synthetic biology integrates engineering principles with biological systems to design and construct novel biological components, devices, and systems. The field has evolved significantly from traditional genetic engineering approaches toward advanced platforms that enable precise and programmable control of cellular behavior. This transformation has been accelerated by rapid advancements in DNA sequencing and synthesis technologies, computational biology tools, and deeper insights into biological system design. The ecosystem spans enabling inputs such as oligonucleotides, enzymes, and chassis organisms, core outputs including synthetic genes, engineered cells, and DNA libraries, and downstream applications across pharmaceuticals, industrial chemicals, biofuels, and biomaterials. Increasing adoption of genome editing technologies, particularly CRISPR-based platforms, is further expanding applications across healthcare, agriculture, and industrial biotechnology, supporting broad-based market growth.
The enabled products segment accounted for 67.5% share in 2025 and is expected to grow at a CAGR of 17.4% through 2035. This segment leads the market as it includes commercially deployable outputs such as engineered biomolecules, industrial enzymes, bio-based chemicals, sustainable fuels, advanced materials, agricultural biologicals, and therapeutic solutions. Strong revenue generation is supported by direct industrial commercialization and widespread integration across multiple end-use sectors.
The pharmaceuticals and diagnostics segment held a 78.8% share in 2025 and is projected to grow at a CAGR of 17.2% through 2035. It remains the most established application area, driven by engineered biological systems in drug discovery, vaccine development, gene and cell therapy research, and molecular diagnostics. Synthetic biology enables highly precise, reproducible, and customizable medical solutions, accelerating the development of advanced therapeutic and diagnostic platforms.
North America Synthetic Biology Market accounted for 39.6% share in 2025. The region maintains a strong position due to advanced research infrastructure, early adoption of biotechnology innovations, and a highly developed ecosystem that includes academic institutions, startups, and large biotechnology and pharmaceutical companies, supporting continuous technological advancement and commercialization.
Major players operating in the Global Synthetic Biology Industry include Twist Bioscience, GenScript, Integrated DNA Technologies, Thermo Fisher Scientific, Novozymes, BASF, Royal DSM, Amyris, Gevo Inc, and Bristol-Myers Squibb. Companies in the Synthetic Biology Market are prioritizing heavy investment in advanced genome engineering platforms, including CRISPR-based technologies and automated DNA synthesis systems, to improve precision and scalability. They are strengthening R&D capabilities through collaborations with academic institutions and biotechnology startups to accelerate innovation pipelines. Expansion into high-growth application areas such as therapeutics, sustainable chemicals, and industrial bioproducts is also a key focus to diversify revenue streams. Firms are increasingly adopting integrated platform strategies that combine software, automation, and biological design tools to reduce development timelines. Strategic partnerships and licensing agreements are being used to access proprietary technologies and expand global reach. In addition, companies are investing in scalable biomanufacturing infrastructure to support commercialization, while also focusing on regulatory compliance and quality assurance to ensure safe and efficient market adoption.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology & Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Product Type, 2022-2035 (USD Million)
Chapter 6 Market Estimates and Forecast, by Technology, 2022-2035 (USD Million)
Chapter 7 Market Estimates and Forecast, by Application, 2022-2035 (USD Million)
Chapter 8 Market Estimates and Forecast, by Region, 2022-2035 (USD Million)
Chapter 9 Company Profiles
Companies Mentioned
The companies profiled in this Synthetic Biology market report include:- Novozymes
- BASF
- GenScript
- ATUM
- Integrated DNA Technologies
- Twist Bioscience
- Biomax Informatics
- Pareto Biotechnologies
- Blue Heron
- TeselaGen Syntax
- Thermo Fisher Scientific
- Gevo Inc
- Royal DSM
- Bristol-Myers Squibb
- Amyris
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 210 |
| Published | April 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 25.6 Billion |
| Forecasted Market Value ( USD | $ 128.1 Billion |
| Compound Annual Growth Rate | 17.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
